Nuvectis Gets FDA Fast-Track Designation for NXP800 in Ovarian Cancer
By Colin Kellaher
Nuvectis Pharma Inc. on Thursday said the U.S. Food and Drug
Administration granted fast-track designation to its NXP800 drug
candidate in a form of ovarian cancer.
The Fort Lee, N.J., biopharmaceutical company said the
designation covers NXP800 for the treatment of platinum-resistant,
ARID1A-mutated ovarian carcinoma.
The FDA's fast-track program is designed to facilitate the
development and expedite the review of treatments for serious or
potentially life-threatening illnesses with high unmet medical
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
December 01, 2022 08:30 ET (13:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.